Product Description
a potent, highly selective blocker with an excellent preclinical in vitro ADME and safety profile. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/30538065/)
Mechanisms of Action: Voltage-Gated Sodium Channel
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Pfizer
Company Location: Eastern America
Company Founding Year: 1849
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers|Pain Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01776619 |
B5281002 | P1 |
Completed |
Healthy Volunteers |
2013-11-01 |
2019-03-19 |
||
NCT01812265 |
B5281003 | P1 |
Completed |
Healthy Volunteers|Pain Unspecified |
2013-08-01 |
2019-03-19 |
Treatments |
|
NCT01797796 |
B5281005 | P1 |
Completed |
Healthy Volunteers |
2013-07-01 |
2019-03-19 |
Treatments |
|
NCT01747941 |
B5281001 | P1 |
Completed |
Healthy Volunteers |
2013-05-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|